Splenectomy in ITP: we keep removing a healthy functional organ

Zurück zum Zitat Lozano ML, Revilla N, Gonzalez-Lopez TJ, Novelli S, González-Porras JR, Sánchez-Gonzalez B, Bermejo N, Pérez S, Lucas FJ, Álvarez MT, Arilla MJ, Perera M, do Nascimento J, Campos RM, Casado LF, Vicente V (2016) Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines. Ann Hematol 95:1089–1098. doi:10.1007/s00277-016-2665-3 CrossRefPubMed Lozano ML, Revilla N, Gonzalez-Lopez TJ, Novelli S, González-Porras JR, Sánchez-Gonzalez B, Bermejo N, Pérez S, Lucas FJ, Álvarez MT, Arilla MJ, Perera M, do Nascimento J, Campos RM, Casado LF, Vicente V (2016) Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines. Ann Hematol 95:1089–1098. doi:10.​1007/​s00277-016-2665-3 CrossRefPubMed

Zurück zum Zitat Rodeghiero F, Ruggeri M (2014) ITP and international guidelines: what do we know, what do we need? Presse Med 43:e61–67. doi:10.1016/j.lpm.2014.02.004 CrossRefPubMed Rodeghiero F, Ruggeri M (2014) ITP and international guidelines: what do we know, what do we need? Presse Med 43:e61–67. doi:10.​1016/​j.​lpm.​2014.​02.​004 CrossRefPubMed

Zurück zum Zitat Deuson R, Danese M, Mathias SD, Schoonen M, Fryzek J (2012) The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim. J Med Econ 15:956–976. doi:10.3111/13696998.2012.688902 CrossRefPubMed Deuson R, Danese M, Mathias SD, Schoonen M, Fryzek J (2012) The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim. J Med Econ 15:956–976. doi:10.​3111/​13696998.​2012.​688902 CrossRefPubMed

Zurück zum Zitat Theilacker C, Ludewig K, Serr A, Schimpf J, Held J, Bögelein M, Bahr V, Rusch S, Pohl A, Kogelmann K, Frieseke S, Bogdanski R, Brunkhorst FM, Kern WV (2016) Splenectomy, pneumococcus, and fulminant infection (SPLEEN OFF) study group. overwhelming postsplenectomy infection: a prospective multicenter cohort study. Clin Infect Dis 62:871–878. doi:10.1093/cid/civ1195 CrossRefPubMed Theilacker C, Ludewig K, Serr A, Schimpf J, Held J, Bögelein M, Bahr V, Rusch S, Pohl A, Kogelmann K, Frieseke S, Bogdanski R, Brunkhorst FM, Kern WV (2016) Splenectomy, pneumococcus, and fulminant infection (SPLEEN OFF) study group. overwhelming postsplenectomy infection: a prospective multicenter cohort study. Clin Infect Dis 62:871–878. doi:10.​1093/​cid/​civ1195 CrossRefPubMed

Zurück zum Zitat Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O (2014) Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica 99:392–398. doi:10.3324/haematol.2013.092460 CrossRefPubMedPubMedCentral Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O (2014) Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica 99:392–398. doi:10.​3324/​haematol.​2013.​092460 CrossRefPubMedPubMedCentral

Zurück zum Zitat Moulis G, Lapeyre-Mestre M, Mahévas M, Montastruc JL, Sailler L (2015) Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. Am J Hematol 90:301–305. doi:10.1002/ajh.23930 CrossRefPubMed Moulis G, Lapeyre-Mestre M, Mahévas M, Montastruc JL, Sailler L (2015) Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. Am J Hematol 90:301–305. doi:10.​1002/​ajh.​23930 CrossRefPubMed

Zurück zum Zitat Gonzalez-Porras JR, Escalante F, Pardal E, Sierra M, Garcia-Frade LJ, Redondo S, Arefi M, Aguilar C, Ortega F, de Cabo E, Fisac RM, Sanz O, Esteban C, Alberca I, Sanchez-Barba M, Santos MT, Fernandez A, Gonzalez-Lopez TJ (2013) Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia. Eur J Haematol 91:236–341. doi:10.1111/ejh.12146 CrossRefPubMed Gonzalez-Porras JR, Escalante F, Pardal E, Sierra M, Garcia-Frade LJ, Redondo S, Arefi M, Aguilar C, Ortega F, de Cabo E, Fisac RM, Sanz O, Esteban C, Alberca I, Sanchez-Barba M, Santos MT, Fernandez A, Gonzalez-Lopez TJ (2013) Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia. Eur J Haematol 91:236–341. doi:10.​1111/​ejh.​12146 CrossRefPubMed

Zurück zum Zitat Chugh S, Darvish-Kazem S, Lim W, Crowther MA, Ghanima W, Wang G, Heddle NM, Kelton JG, Arnold DM (2015) Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol 2:e75–81. doi:10.1016/S2352-3026(15)00003-4 CrossRefPubMed Chugh S, Darvish-Kazem S, Lim W, Crowther MA, Ghanima W, Wang G, Heddle NM, Kelton JG, Arnold DM (2015) Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol 2:e75–81. doi:10.​1016/​S2352-3026(15)00003-4 CrossRefPubMed

Zurück zum Zitat Michel M, Wasser J, Godeau B, Aledort L, Cooper N, Tomiyama Y, Khellaf M, Wang X (2015) Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia. Ann Hematol 94:1973–1980. doi:10.1007/s00277-015-2485-x CrossRefPubMed Michel M, Wasser J, Godeau B, Aledort L, Cooper N, Tomiyama Y, Khellaf M, Wang X (2015) Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia. Ann Hematol 94:1973–1980. doi:10.​1007/​s00277-015-2485-x CrossRefPubMed

Zurück zum Zitat Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK (2015) Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet 386:1649–58. doi:10.1016/S0140-6736(15)61107-2 CrossRefPubMed Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK (2015) Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet 386:1649–58. doi:10.​1016/​S0140-6736(15)61107-2 CrossRefPubMed

Zurück zum Zitat González-López TJ, Pascual C, Álvarez-Román MT, Fernández-Fuertes F, Sánchez-González B, Caparrós I, Jarque I, Mingot-Castellano ME, Hernández-Rivas JA, Martín-Salces M, Solán L, Beneit P, Jiménez R, Bernat S, Andrade MM, Cortés M, Cortti MJ, Pérez-Crespo S, Gómez-Núñez M, Olivera PE, Pérez-Rus G, Martínez-Robles V, Alonso R, Fernández-Rodríguez A, Arratibel MC, Perera M, Fernández-Miñano C, Fuertes-Palacio MA, Vázquez-Paganini JA, Gutierrez-Jomarrón I, Valcarce I, de Cabo E, Sainz A, Fisac R, Aguilar C, Paz Martínez-Badas M, Peñarrubia MJ, Calbacho M, de Cos C, González-Silva M, Coria E, Alonso A, Casaus A, Luaña A, Galán P, Fernández-Canal C, Garcia-Frade J, González-Porras JR (2015) Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol 90:E40–3. doi:10.1002/ajh.23900 CrossRefPubMed González-López TJ, Pascual C, Álvarez-Román MT, Fernández-Fuertes F, Sánchez-González B, Caparrós I, Jarque I, Mingot-Castellano ME, Hernández-Rivas JA, Martín-Salces M, Solán L, Beneit P, Jiménez R, Bernat S, Andrade MM, Cortés M, Cortti MJ, Pérez-Crespo S, Gómez-Núñez M, Olivera PE, Pérez-Rus G, Martínez-Robles V, Alonso R, Fernández-Rodríguez A, Arratibel MC, Perera M, Fernández-Miñano C, Fuertes-Palacio MA, Vázquez-Paganini JA, Gutierrez-Jomarrón I, Valcarce I, de Cabo E, Sainz A, Fisac R, Aguilar C, Paz Martínez-Badas M, Peñarrubia MJ, Calbacho M, de Cos C, González-Silva M, Coria E, Alonso A, Casaus A, Luaña A, Galán P, Fernández-Canal C, Garcia-Frade J, González-Porras JR (2015) Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol 90:E40–3. doi:10.​1002/​ajh.​23900 CrossRefPubMed